---
title: "FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288365897.md"
description: "FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News"
datetime: "2026-06-01T21:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288365897.md)
  - [en](https://longbridge.com/en/news/288365897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288365897.md)
generator: "portal-rs"
---

# FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting | RHHBY Stock News

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $1.53 billion](https://longbridge.com/en/news/297652647.md)
- [Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion](https://longbridge.com/en/news/297692233.md)
- [12:49 ETSimcere Zaiming signe un accord de licence exclusif avec Roche pour le développement mondial du SIM0660](https://longbridge.com/en/news/297813196.md)
- [04:00 ETSimcere Zaiming sluit exclusieve licentieovereenkomst met Roche voor wereldwijde ontwikkeling van SIM0660](https://longbridge.com/en/news/297751599.md)
- [Gyre Therapeutics outlines protein degrader pipeline, China commercial outlook in corporate presentation](https://longbridge.com/en/news/297654775.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**